18889881171
Kalkine 0
countryflagUS

Astellas Pharma Inc

Healthcare US ALPMY

9.41USD
0.03(0.32%)

Last update at 2025-05-19T18:44:00Z

Day Range

9.359.45
LowHigh

52 Week Range

9.3513.14
LowHigh

Fundamentals

  • Previous Close 9.38
  • Market Cap18695.01M
  • Volume16407
  • P/E Ratio52.20
  • Dividend Yield-%
  • EBITDA365892.99M
  • Revenue TTM1772155.04M
  • Revenue Per Share TTM989.13
  • Gross Profit TTM 1043154.00M
  • Diluted EPS TTM0.20

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Type yearly yearly yearly yearly yearly
Date 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Income before tax 132361.00M 156886.00M 145324.00M 245350.00M 248967.00M
Minority interest - - - - 0.00000M
Net income 98714.00M 124086.00M 120589.00M 195411.00M 222265.00M
Selling general administrative 630272.00M 548840.00M 504316.00M 499295.00M 490263.00M
Selling and marketing expenses - - - - -
Gross profit 1230266.00M 1043154.00M 1003465.00M 1024104.00M 1014298.00M
Reconciled depreciation 105738.00M 79684.00M 72652.00M 66396.00M 63458.00M
Ebit 140928.00M 137601.00M 147659.00M 248354.00M 250269.00M
Ebitda 246666.00M 217285.00M 220311.00M 314750.00M 313727.00M
Depreciation and amortization 105738.00M 79684.00M 72652.00M 66396.00M 63458.00M
Non operating income net other - - - - 0.00000M
Operating income 133029.00M 155686.00M 136051.00M 243991.00M 243912.00M
Other operating expenses 1387062.00M 1165200.00M 1113955.00M 1055191.00M 1060810.00M
Interest expense 8779.00M 4949.00M 2335.00M 3004.00M 1302.00M
Tax provision 33647.00M 32800.00M 24734.00M 49939.00M 26702.00M
Interest income 8110.00M 6149.00M 11608.00M 4363.00M 6358.00M
Net interest income -669.00000M 1200.00M 9273.00M 1359.00M 5056.00M
Extraordinary items - - - - 0.00000M
Non recurring - - - - 0.00000M
Other items - - - - 0.00000M
Income tax expense 33647.00M 32800.00M 24734.00M 49939.00M 26702.00M
Total revenue 1518619.00M 1296163.00M 1249528.00M 1300843.00M 1306348.00M
Total operating expenses 1098709.00M 912191.00M 867892.00M 778452.00M 768760.00M
Cost of revenue 288353.00M 253009.00M 246063.00M 276739.00M 292050.00M
Total other income expense net -99291.00000M -61259.00000M -105609.00000M -22133.00000M -33449.00000M
Discontinued operations - - - - 0.00000M
Net income from continuing ops 98714.00M 124086.00M 120590.00M 195411.00M 222265.00M
Net income applicable to common shares - 124086.00M 120589.00M 195411.00M 222265.00M
Preferred stock and other adjustments - - - - 0.00000M
Breakdown 2024-03-31 2023-03-31 2022-03-31 2021-03-31 2020-03-31
Type yearly yearly yearly yearly yearly
Date 2024-03-31 2023-03-31 2022-03-31 2021-03-31 2020-03-31
Total assets 3569603.00M 2456518.00M 2332395.00M 2273628.00M 2318160.00M
Intangible assets 1453824.00M 562496.00M 623431.00M 651427.00M 738507.00M
Earning assets - - - - -
Other current assets 46536.00M 32428.00M 28998.00M 19658.00M 18049.00M
Total liab 1973615.00M 948564.00M 872087.00M 887513.00M 1028992.00M
Total stockholder equity 1595988.00M 1507954.00M 1460308.00M 1386115.00M 1289168.00M
Deferred long term liab - - - - -
Other current liab 589739.00M 585798.00M 556672.00M 467595.00M 626754.00M
Common stock 103001.00M 103001.00M 103001.00M 103001.00M 103001.00M
Capital stock 103001.00M 103001.00M 103001.00M 103001.00M 103001.00M
Retained earnings 809400.00M 908158.00M 944261.00M 953289.00M 905851.00M
Other liab - 106852.00M 128986.00M 152578.00M 157915.00M
Good will 418694.00M 328411.00M 303030.00M 284011.00M 267510.00M
Other assets - 84170.00M 72330.00M 54175.00M 52875.00M
Cash 335687.00M 376840.00M 315986.00M 326128.00M 318391.00M
Cash and equivalents - - - - -
Total current liabilities 1285725.00M 726034.00M 687411.00M 592372.00M 798708.00M
Current deferred revenue 38515.00M - - - -
Net debt 584329.00M -376840.00000M -315986.00000M -326128.00000M -318391.00000M
Short term debt 472278.00M - - - -
Short long term debt 472278.00M - - - -
Short long term debt total 920016.00M - - - -
Other stockholder equity 683587.00M -1011159.00000M -1047262.00000M -1056290.00000M -1008852.00000M
Property plant equipment - 286459.00M 269044.00M 264623.00M 268600.00M
Total current assets 1194730.00M 1049954.00M 923354.00M 872588.00M 867514.00M
Long term investments - - - - -
Net tangible assets - - 533847.00M 450677.00M 283151.00M
Short term investments 28784.00M 19784.00M 21297.00M 5560.00M 9459.00M
Net receivables 534985.00M 446516.00M 404001.00M 357162.00M 370598.00M
Long term debt 447738.00M - - - -
Inventory 248738.00M 174386.00M 153072.00M 164080.00M 151017.00M
Accounts payable 185193.00M 140236.00M 130739.00M 124777.00M 171954.00M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 533301.00M - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 45595.00M 1.00M -1.00000M -1.00000M -1.00000M
Deferred long term asset charges - - - - -
Non current assets total 2374873.00M 1406564.00M 1409041.00M 1401040.00M 1450646.00M
Capital lease obligations - - - - -
Long term debt total - - - - -
Breakdown 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Type yearly yearly yearly yearly yearly
Date 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Investments -84500.00000M -62413.00000M -81894.00000M -389793.00000M -41757.00000M
Change to liabilities 0.00000M -10101.00000M -51569.00000M -21363.00000M 40828.00M
Total cashflows from investing activities - -62413.00000M -81894.00000M -389793.00000M -41757.00000M
Net borrowings -15000.00000M -60000.00000M -126000.00000M 326000.00M 326000.00M
Total cash from financing activities -195623.00000M -216298.00000M -229479.00000M 181055.00M -233681.00000M
Change to operating activities - -16639.00000M 47389.00M -10400.00000M 20.00M
Net income 132361.00M 156886.00M 145324.00M 245350.00M 248967.00M
Change in cash 60854.00M -10142.00000M 7737.00M 7317.00M -20657.00000M
Begin period cash flow 315986.00M 326128.00M 318391.00M 311074.00M 331731.00M
End period cash flow 376840.00M 315986.00M 326128.00M 318391.00M 311074.00M
Total cash from operating activities 327767.00M 257444.00M 306843.00M 221998.00M 258630.00M
Issuance of capital stock - - - - -
Depreciation 105738.00M 79684.00M 72652.00M 66396.00M 63458.00M
Other cashflows from investing activities - -10017.00000M 3632.00M 1935.00M 8714.00M
Dividends paid -100355.00000M -85236.00000M -76157.00000M -73539.00000M 72066.00M
Change to inventory -7086.00000M 24058.00M -2318.00000M -6038.00000M -5480.00000M
Change to account receivables -4849.00000M -8001.00000M 22161.00M -16391.00000M -25640.00000M
Sale purchase of stock -60556.00000M -50717.00000M -9163.00000M -52899.00000M -160442.00000M
Other cashflows from financing activities -3217.00000M -2530.00000M -2268.00000M 307493.00M -1173.00000M
Change to netincome 15688.00M 31557.00M 73204.00M -35556.00000M -63523.00000M
Capital expenditures 88541.00M 76448.00M 77441.00M 77888.00M 52128.00M
Change receivables - - - - 0.00000M
Cash flows other operating - - - - 0.00000M
Exchange rate changes - - - - 0.00000M
Cash and cash equivalents changes - - - - 0.00000M
Change in working capital -24209.00000M 5956.00M -31726.00000M -43792.00000M 9708.00M
Stock based compensation - - - - -
Other non cash items 113877.00M 14918.00M 120593.00M -45956.00000M -63503.00000M
Free cash flow 239226.00M 180996.00M 229402.00M 144110.00M 206502.00M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - General

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ALPMY
Astellas Pharma Inc		 0.03 0.32% 9.41 52.20 12.82 0.01 1.85 1.93 12.69
LLY
Eli Lilly and Company		 -7.505 0.99% 749.88 78.14 31.95 16.34 45.83 16.65 54.36
JNJ
Johnson & Johnson		 0.82 0.54% 152.15 29.17 14.33 3.74 5.18 3.80 15.22
ABBV
AbbVie Inc		 1.25 0.68% 185.26 61.52 14.86 5.62 51.62 6.76 20.58
MRK
Merck & Company Inc		 0.95 1.26% 77.02 59.83 12.33 4.50 6.47 4.94 23.79

Reports Covered

Stock Research & News

View All

Profile

Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants. Th company has a research collaboration with Vivtex Corporation to evaluate Vivtex's GI-ORIS screening and formulation platform technology to support the development of novel and oral versions of a therapeutic candidate provided by Astellas; and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution. The company was founded in 1923 and is headquartered in Tokyo, Japan.

Astellas Pharma Inc

2-5-1, Nihonbashi-Honcho, Tokyo, Japan, 103-8411

Key Executives

Name Title Year Born
Mr. Kenji Yasukawa Ph.D. Pres, CEO & Chairman 1960
Mr. Naoki Okamura BSc Exec. VP, Chief Strategy Officer & Representative Director NA
Minoru Kikuoka CFO & Sr. Managing Exec. Officer NA
Nobue Yasuda Gen. Mang. of Fin. & Accounting Department NA
Mr. Yoshitsugu Shitaka Ph.D. Chief Scientific Officer & Sr. Managing Exec. Officer NA
Ms. Catherine B. Levitt Gen. Counsel NA
Mr. Katsuyoshi Sugita Chief People Officer and Chief Ethics & Compliance Officer NA
Mr. Stig Ogata VP of Corp. Communications NA
Ms. Collette Taylor Sr. VP of HR 1963
Chihiro Yokota Sr. Corp. Exec. and Head of Japan/Asia Devel., Devel. NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.